NSCLC

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  

NSCLC
Jan 26, 2025, 12:01 | Blog
Jordi Remon: Teliso-V and osimertinib - the METamorphosis of EGFR-mutant lung cancer?
Jordi Remon, Thoracic oncologist at CIOCC Barcelona, shared on X: "TelisoV+Osi potential ttx in MET overex…
Jan 25, 2025, 12:41 | Insight
Elvina Almuradova: Targeting c-MET overexpression is reshaping EGFR-mutant NSCLC treatment
Elvina Almuradova, Oncology Unit Lead at Can Hospitals Turkey, shared a post on X: “Breaking News from…
Jan 25, 2025, 04:12 | Science
Jarushka Naidoo: De-Escalation Strategies With ICIs in NSCLC - Do We Already Have Enough Evidence?
Jarushka Naidoo, Thoracic oncologist at the Beaumont Hospital Dublin, shared a post on X about…
Jan 25, 2025, 03:46 | Insight
Estela Rodriguez: Using nivolumab plus ipilimumab as a treatment to patients with metastatic NSCLC
Estela Rodriguez, Associate Director of Community Outreach and Co-Lead of the Thoracic Site Disease Group…
Jan 25, 2025, 02:59 | Blog
Assessing active immune pathways in NSCLC - JTO and JCO CRR
JTO and JCO CRR shared a post on X: "This study proposes a diagnostic shift…
Jan 23, 2025, 16:29 | Drugs
FDA approval: Zenocutuzumab for NRG1+ NSCLC - IASLC
The International Association for the Study of Lung Cancer (IASLC) shared a post on X:…
Jan 23, 2025, 14:32 | Blog
Oscar Tahuahua: ctDNA could offer hope for NSCLC management
Oscar Tahuahua, Medical Oncology Fellow at National Cancer Institute (Mexico), shared an article by Nicola Normanno…
Jan 21, 2025, 17:00 | Insight
5 papers about lung cancer by Stephen Liu
Stephen Liu, Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a few must-reads papers…
Jan 20, 2025, 17:13 | Blog
Jarushka Naidoo: Suresh S. Ramalingam on targeted therapy for early stage NSCLC
Jarushka Naidoo, Thoracic oncologist at the Beaumont Hospital Dublin (Ireland), shared a post on X:…
Jan 20, 2025, 16:03 | Science
Amy Moore: Biomarker testing can help identify actionable mutations in patients with squamous NSCLC
Amy Moore, Vice President of Global Engagement and Patient Partnerships at LUNGevity Foundation, shared a…
Jan 20, 2025, 14:16 | Insight
Amy Moore: Ensuring that all patients benefit from recent scientific advances in lung cancer
Amy Moore, Vice President of Global Engagement and Patient Partnerships at LUNGevity Foundation, shared a…
Jan 19, 2025, 14:12 | Science
Khalil Choucair: Potential biomarkers of IO-therapy in patients of extremes of age
Khalil Choucair, Chief Fellow of Hematology & Oncology at Karmanos Cancer Institute, reshared a post…
Jan 19, 2025, 13:47 | Insight
Amy Moore: Are patients with RET+ NSCLC on TKIs protected against cachexia?
Amy Moore, Vice President of Global Engagement and Patient Partnerships at LUNGevity Foundation, shared a…
Jan 19, 2025, 12:58 | Blog
The Long-Term Health Consequences of Radiation Therapy: A Personal Story of Survivorship and Advocacy
Heidi Nafman-Onda, founder of The White Ribbon Project, shares her personal experience navigating the challenges…
Jan 17, 2025, 14:52 | Science
Marcelo Negrao: Co-mutations and transcriptional signatures in non-small cell lung cancer patients
Marcelo Negrao, Assistant Professor of Medical Oncology at MD Anderson Cancer Center, shared his recent…
Jan 16, 2025, 14:16 | Science
Cecilia Pompili: Terrific paper from Dr Melinda L. Hsu on unmet needs and QoL in NSCLC survivors
Cecilia Pompili, Associate Professor and Thoracic Surgeon focusing on Patient Reported Outcomes Research at the…
Jan 16, 2025, 08:42 | Insight
Hidehito Horinouchi: Telisotuzumab Vedotin and Osimertinib in EGFR-Mutated NSCLC
Hidehito Horinouchi, Assistant Chief of the National Cancer Center Hospital, shared a post on X…
Jan 15, 2025, 18:19 | Blog
Antonio Passaro: COCOON study meets primary endpoint
Antonio Passaro, Lung cancer oncologist & researcher at Instituto Europeo di Oncologia, shared a post…
Jan 14, 2025, 18:08 | Insight
New Research Highlight: Amivantamab With TKIs for Advanced NSCLC - ALK Positive Inc.
ALK Positive Inc. shared a post on LinkedIn: "New Research Highlight: Amivantamab With TKIs for…
Jan 14, 2025, 18:02 | Insight
MD Anderson Research Highlights
Featuring molecular insights into cancer cell progression, novel predictive biomarkers for multiple cancer types, and…
Jan 14, 2025, 12:19 | Science
5 papers about Lung Cancer suggested by Stephen Liu
Stephen Liu, Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a few must-reads papers…
Jan 14, 2025, 02:50 | Blog
Phase 1b study of telisotuzumab vedotin in combination with osimertinib for NSCLC
Yakup Ergün Medical Oncologist at Antalya City Hospital shared on X: "Results from a phase…
Jan 13, 2025, 20:21 | Insight
Navneet Singh: Expert consensus statement on the peri-operative management of NSCLC
Navneet Singh, Thoracic Medical Oncologist at the Postgraduate Institute of Medical Education and Research, shared…
Jan 13, 2025, 04:50 | Insight
Hidehito Horinouchi: Potential long-term clinical benefit from CheckMate 816
Hidehito Horinouchi, Assistant Chief of the National Cancer Center Hospital, shared a post on X…
Jan 12, 2025, 19:21 | Blog
Avrum Spira: Expanded collaboration with Ankyra Therapeutics for local immunotherapy in NSCLC
Avrum Spira, Global Head of the Interventional Oncology R&D Unit at Johnson and Johnson, shared…
Jan 12, 2025, 13:43 | Science
Dipesh Uprety: TROPION-Lung05 - a phase II trial on NSCLC by Jacob Sands et al.
Dipesh Uprety, Assistant Professor of Thoracic Oncology at Karmanos Cancer Institute, shared a post on X…
Jan 12, 2025, 12:56 | Insight
Tom Cavanaugh: Inspired by the topline results from the Phase 3 MARIPOSA study
Tom Cavanaugh, Company Group Chairman at Johnson and Johnson Innovative Medicine, shared a post on…
Jan 11, 2025, 17:09 | Science
Biomarker testing in lung cancer: from bench to bedside
Brittney Abernathy, Journal Manager at Frontiers, shared a recent article by Ullas Batra on LinkedIn:…
Jan 11, 2025, 16:54 | Insight
Patrick Forde: Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer
Patrick Forde, Professor at Johns Hopkins University, shared a post on X about a recent…
Jan 11, 2025, 14:36 | Insight
Simon Heeke: Analysing ctDNA and ctRNA to improve detection of ALK rearrangements in NSCLC
Simon Heeke, Assistant Professor at MD Anderson Cancer Center, shared a post on LinkedIn: “Excited…
Jan 11, 2025, 10:13 | Blog
Neoadjuvant Ipilimumab, Nivolumab vs Chemotherapy in NSCLC
Jarushka Naidoo shared on X: "Neoadj Ipi, Nivo v Chemo in NSCLC 221patients, I+Nx3 v…
Jan 10, 2025, 17:01 | Insight
Biagio Ricciuti: Datopotamab Deruxtecan in Advanced/Metastatic NSCLC by Jacob Sands et al.
Biagio Ricciuti, Thoracic Medical Oncologist at the Dana-Farber Cancer Institute, shared a post on X about…
Jan 9, 2025, 11:42 | Insight
Hidehito Horinouchi: ATORG expert consensus statement on the peri-operative management of NSCLC
A recent paper by Stephanie Saw, Medical Oncologist at National Cancer Centre Singapore, was mentioned…
Jan 8, 2025, 15:17 | Insight
Johnson and Johnson has announced positive topline results from the Phase 3 MARIPOSA study
The MARIPOSA study's findings position RYBREVANT plus LAZCLUZE as the first regimen to show a survival…
Jan 8, 2025, 12:38 | Blog
Antonio Passaro: Major Breakthrough Announced - MARIPOSA Study Results
Antonio Passaro, Medical Oncologist and a Medical Director with High Specialization Assignment at the European…
Jan 8, 2025, 11:33 | Career
OncoInfluencers to Follow on Social Media: Dr. Antonio Passaro
We’re excited to feature Dr. Antonio Passaro, a distinguished leader in lung cancer research and…
Jan 7, 2025, 14:28 | Science
Valuable insights from a new article on Unresectable Stage IIIA/IIIB NSCLC - IU Simon Comprehensive Cancer Center
IU Simon Comprehensive Cancer Center shared a post on LinkedIn about a recent paper by…
Jan 7, 2025, 13:33 | Insight
5 papers about Lung Cancer suggested by Stephen Liu
Stephen Liu, Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a few must-reads papers…
Jan 7, 2025, 09:46 | Science
Glecirasib in KRASG12C-mutated non-small cell lung cancer by Yuankai Shi et al.
Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared a post on X about a…
Jan 6, 2025, 09:48 | Insight
Amy Moore: PD-1/VEGF combos are a strategy to watch in lung cancer
Amy Moore, Vice President of Global Engagement and Patient Partnerships at LUNGevity Foundation, shared a…
Jan 5, 2025, 14:23 | Science
Andrea Boutros: Can fewer cycles of immunotherapy deliver the same results?
Andrea Boutros, a Medical Doctor and Oncology Resident at San Martino Polyclinic Hospital shared a…
Jan 3, 2025, 21:19 | Science
Luis Raez: We have a lot of survivors on osimertinib alone that will need second-line therapy in the future
Luis Raez, Medical Director and Chief Scientific Officer at Memorial Cancer Institute, shared a post…
Jan 3, 2025, 16:25 | Science
Amivantamab Plus Lazertinib in Patients With EGFR-mutant NSCLC by Benjamin Besse et al.
A recent article by Benjamin Besse et al. was mentioned by Akhil Santhosh, Medical Oncology Specialist at…
Jan 3, 2025, 16:22 | Science
Expert consensus statement on the peri-operative management of NSCLC by Stephanie Saw et al.
A recent article by Stephanie Saw et al. was mentioned by Yakup Ergün, Medical Oncologist at…
Jan 3, 2025, 15:57 | Blog
High peripheral T cell diversity associated with lower risk of toxicity to dual ICI Therapy - JITC
Journal for ImmunoTherapy of Cancer shared a post on X: “New JITC article: High peripheral…
Jan 2, 2025, 15:18 | Science
Akhil Santhosh: Can SCLC molecular subtypes guide therapy?
Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, posted on X:…
Dec 31, 2024, 19:54 | Blog
Antonio Passaro: An important milestone in the treatment of advanced NSCLC with common EGFR mutations
Antonio Passaro, Medical oncologist at the European Institute of Oncology in Milan, posted on LinkedIn:…
Dec 30, 2024, 08:49 | Science
Alessio Cortellini: Strength lies in collaboration
Alessio Cortellini, Consultant Medical Oncologist and Assistant Professor at UCBM, reshared a post by Elio…
Dec 29, 2024, 12:05 | Blog
Amy C. Moore: 2024 was an exciting year for lung cancer advances
Amy C. Moore, Vice President of Global Engagement and Patient Partnerships at LUNGevity Foundation, shared…
Dec 29, 2024, 10:21 | Insight
Existing biomarkers predicting ICI treatment response in advanced NSCLC
JAMA Oncology shared a post on X: “A deep learning AI model showed improved accuracy…
Dec 29, 2024, 10:10 | Science
Neoadjuvant atezolizumab plus chemotherapy for resectable NSCLC
Journal for ImmunoTherapy of Cancer posted on X about recent paper by Brian S. Henick…
Dec 29, 2024, 10:00 | Drugs
Giannis Mountzios: 10 exciting compounds that will shape lung cancer in 2025
Giannis Mountzios, Consultant Medical Oncologist at the Department of Medical Oncology in the Air force…
Dec 28, 2024, 18:07 | Science
Fawzi Abu Rous: The efficacy and safety of anti-angiogenesis agents in patients with squamous lung cancer
Fawzi Abu Rous, Thoracic Medical Oncologist at Henry Ford Health, shared a recent article on…
Dec 28, 2024, 09:40 | Science
5 papers about Lung Cancer suggested by Stephen Liu
Stephen Liu, Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a few must-reads papers…
Dec 27, 2024, 17:00 | Science
Corinne Faivre-Finn: An International EORTC Survey on Stage III NSCLC resectability
Corinne Faivre-Finn, Professor of Thoracic Radiation Oncology at the University of Manchester, posted on X…
Dec 27, 2024, 16:29 | Blog
Drew Moghanaki: The PACIFIC-5 study results are finally available
Drew Moghanaki, Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA,…
Dec 26, 2024, 15:22 | Insight
Ilias Houda: Our EORTC survey on resectability of stage III NSCLC
Ilias Houda, PhD Candidate in Thoracic Oncology at Amsterdam UMC, shared a post on LinkedIn…
Dec 25, 2024, 22:32 | Insight
Stephen Liu: Perioperative osimertinib for resectable EGFR NSCLC
Stephen Liu, Associate Professor of Medicine at Georgetown University, shared a post on X: “Perioperative…
Dec 25, 2024, 15:16 | Science
Treatment Selection for the High-risk Patient with Stage I NSCLC
Drew Moghanaki, Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA,…
Dec 25, 2024, 15:09 | Blog
Stephanie Saw: First line and post-progression treatment options for advanced EGFR-mutated NSCLC
Stephanie Saw, Medical Oncologist at National Cancer Center of Singapore, shared a post on X:…
Dec 25, 2024, 13:45 | Blog
Lung Cancer Considered's new episode on Tumor Treating Fields - IASLC
IASLC posted on X: "New episode of Lung Cancer Considered! Narjust Florez and Leal Ticiana…
Dec 25, 2024, 11:07 | Insight
Tagrisso Approved in the EU for Unresectable EGFR-Mutated Lung Cancer
AstraZeneca’s Tagrisso (osimertinib) has been approved in the European Union for the treatment of adult…
Dec 25, 2024, 09:42 | Science
The association of oncogene driver mutations with recurrence and survival in stage I NSCLC
Clinical Lung Cancer shared an article by Daniel M. Libby on X: "Explore a new…
Dec 24, 2024, 17:55 | Blog
Layth Mula-Hussain: Prognostic factors and survival in patients with NSCLC and brain metastases
Layth Mula-Hussain, Radiation Oncologist and Assistant Professor at Dalhousie University, shared on LinkedIn: “Recently released.…
Dec 24, 2024, 00:18 | Blog
Jordi Remon: 2024 - Fortunately it is difficult to merge all treatments for NSCLC
Jordi Remon, Thoracic oncologist at CIOCC Barcelona, shared a post on X: "2024: Fortunately it…
Dec 23, 2024, 20:29 | Science
Alba Fiorentino: An oligometastatic lung cancer case report with a durable complete metabolic response
Alba Fiorentino, Associate Professor of Radiation Oncology at LUM University of Medicine, shared a post…
Dec 23, 2024, 12:47 | Science
Giuseppe Banna: Selpercatinib for RET fusion+ NSCLC by Benjamin Besse et al.
A recent paper by Benjamin Besse, Director of Clinical Research at the Gustave Roussy Institute,…
Dec 22, 2024, 17:26 | Science
Andrea De Giglio: The prognostic role of STK11 mutations in advanced NSCLC treated with first-line IO
Andrea De Giglio, Junior Assistant Professor at University of Bologna, posted on X about recent…
Dec 22, 2024, 13:45 | Science
Details on uncommon EGFR mutations in NSCLC from Dr. Alfredo Addeo
Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared a post on X:…
Dec 22, 2024, 10:44 | Science
5 papers about Lung Cancer suggested by Stephen Liu
Stephen Liu, Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a few must-reads papers…
Dec 21, 2024, 22:35 | Blog
Santiago Viteri: Latest findings from the BR.31 trial presented at the 2024 ESMO Congress
Santiago Viteri, Medical Director at UOMi Cancer Center and Chief Executive Officer at Pratia Sirius,…
Dec 20, 2024, 16:39 | Drugs
FDA has Approved Ensartinib for ALK-Positive Advanced NSCLC
On December 18, 2024, The FDA has approved ensartinib for the treatment of ALK-positive, locally…
Dec 20, 2024, 14:19 | Science
Ravi Parikh: Predicting immunotherapy response in non-small cell lung cancer
Ravi Parikh, Director of Human-Algorithm Collaboration Lab at Winship Cancer Institute of Emory University, shared…
Dec 20, 2024, 10:11 | Blog
Giannis Mountzios: End of story for anti-PD1/TIGIT?
Giannis Mountzios, Director of 4th Oncology Department and Clinical Trials Unit at HENRY DUNANT Hospital…
Dec 19, 2024, 12:01 | Insight
Remon Jordi Discusses Advances in Thoracic Oncology at ESMO Asia 2024
Mediamedic shared a post on LinkedIn: “ESMO Asia 2024, Jordi Remon Masip Highlights Key Thoracic…
Dec 19, 2024, 07:24 | Drugs
U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy
U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage…
Dec 18, 2024, 06:47 | Insight
Lauren Averett Byers has been awarded the 2025 Edith and Peter O’Donnell Award in Medicine
Lauren Averett Byers was honored for Groundbreaking Contributions to Small Cell Lung Cancer Research and…
Dec 17, 2024, 23:14 | Science
Stephen V Liu: Resistance and identification of synthetic lethal targets in KRAS STK11 NSCLC
Stephen V Liu, Associate Professor of Medicine at Georgetown University, posted on X: "Fascinating work…
Dec 17, 2024, 16:18 | Insight
Update on U.S. Regulatory Review of Subcutaneous Amivantamab
Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has issued a…
Dec 17, 2024, 12:59 | Insight
Highlights from IASLC HTTR 2024
HHTR 2024 took place from December 13-15, 2024, at the Hilton Washington DC National Mall…
Dec 16, 2024, 19:13 | Blog
Suresh S. Ramalingam on insurance coverage challenges for Keytruda in NSCLC Patients
Suresh S. Ramalingam, Executive Director of Winship Cancer Institute of Emory University, shared a post…
Dec 16, 2024, 08:33 | Insight
Jarushka Naidoo: KN867 trial shows no EFS benefit for SBRT+Pembro in NSCLC
Jarushka Naidoo, Thoracic Oncologist at the Beaumont Hospital Dublin (Ireland), posted the following on X: “ESMO…
Dec 15, 2024, 19:50 | Opinion
Kunal Jobanputra: One of the largest dataset reporting s-irAE and outcomes in NSCLC by Jarushka Naidoo
Kunal Jobanputra, Medical Oncologist at Tata Memorial Hospital, shared on X: “One of the largest…
Dec 15, 2024, 14:35 | Blog
PROSPECT-Lung Trial: Evaluating Optimal Timing of Immunotherapy for Operable Non-Small Cell Lung Cancer
Innovative Study Led by Dr. Raid Aljumaily Aims to Revolutionize Lung Cancer Treatment and Enhance…
Dec 13, 2024, 16:57 | Insight
Akhil Santhosh: IO added to CTRT doesn't work in stage 3 NSCLC
Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute and Post DM…
Dec 12, 2024, 13:14 | Blog
Razelle Kurzrock: Targeting NRg1 fusions
Razelle Kurzrock, Associate Director of Clinical Research for the Medical College of Wisconsin Cancer Center,…
Dec 11, 2024, 17:56 | Insight
Aakash Desai: A Year of Remarkable Progress in Lung Cancer and Mesothelioma Treatments
Aakash Desai, Assistant Professor at UAB O’Neal Comprehensive Cancer Center, posted on LinkedIn: “A Year…
Dec 11, 2024, 17:44 | Blog
Bicheng Zhang: Post-Resistance Strategies for Third-Generation EGFR-TKIs in NSCLC
Mediamedic shared a post on LinkedIn: "Editor’s Note: EGFR mutations are among the most common…
Dec 11, 2024, 15:48 | Insight
Tumor Methylation Burden in Non-Small Cell Lung Cancer: A New Way of Thinking About Epigenetics
"One of the emerging biomarkers in lung cancer that is gaining attraction is Tumor Methylation…
Dec 11, 2024, 10:33 | Blog
Pemetrexed plus platinum ± pembrolizumab in untreated metastatic nonsquamous NSCLC
ESMO shared on X: "For Annals of Oncology Anniversary we highlight this 2023 top-cited paper:' Pemetrexed…
Dec 11, 2024, 10:30 | Insight
David D. W. Lee: Proud to be a part of the Pan-Asian adapted ESMO Clinical Practice Guideline
David D. W. Lee, Consultant Clinical Oncologist at the University of Malaya Medical Centre and…
Dec 10, 2024, 04:30 | Insight
Texas Lung Cancer Conference 2025
Texas Lung Cancer Conference 2025 will be held from April 10-12, 2025 at Austin, Texas.…
Dec 9, 2024, 14:27 | Insight
Sanjay Popat: The Pan-Asian adapted ESMO Clinical Practice Guidelines for Oncogene Addicted Metastatic NSCLC
Sanjay Popat, Professor at The ICR and Thoracic Oncologist at The Royal Marsden NHS Foundation Trust,…
Dec 8, 2024, 04:47 | Insight
Yvonne Diaz: Study shows family history links to lung cancer risk
Yvonne Diaz, Director of Global Media Relations and Social Media at EY, shared on X:…
Dec 8, 2024, 04:47 | Insight
Exciting developments in the management of unresectable stage III EGFR NSCLC
Aakash Desai, Assistant Professor and Associate Director at UAB O'Neal Comprehensive Cancer Center, shared an…
Dec 8, 2024, 02:56 | Insight
Tejas Patil: First patient with mNSCLC with an EGFR-ERBB4 gene fusion who clinically and radiographically responded to EGFR TKIs
Tejas Patil, Thoracic oncologist at University of Colorado Cancer Center, shared a post on X:…
Dec 7, 2024, 11:04 | Blog
Lorenza Rimassa: Patient Advocate on Immunotherapy Choices in HCC and NSCLC at ESMO Asia 2024
Lorenza Rimassa, Associate Professor of Medical Oncology at HUNIMED, shared a post on X: "Patient…
Dec 5, 2024, 11:01 | Insight
FDA Grants Accelerated Approval to Zenocutuzumab-zbco for NSCLC and Pancreatic Adenocarcinoma
On December 4, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval for…
Dec 4, 2024, 14:36 | Blog
2024 Marks The 20th Anniversary of The Discovery of EGFR in NSCLC
May 2024 Marks The 20th Anniversary of the Publication of Papers on The Role of…
Dec 4, 2024, 00:00 | Blog
ESMO - Practice-changing publications in NSCLC and endometrial cancer critically reviewed by leading experts
ESMO shared on LinkedIn: " Practice-changing publications in NSCLC (LAURA trial) and endometrial cancer (RUBY trial)…
All: 585 Posts: 1 - 100
Special Coverage